(Q37044230)

English

Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?

scientific article published on December 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

1 reference

Europe PubMed Central

Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

author name string

Vibeke Strand

1

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

language of work or name

0 references

publication date

1 December 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

370

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

9605

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

2138-2151

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Do patients with chronic low back pain have a lower level of aerobic fitness than healthy controls?: are pain, disability, fear of injury, working status, or level of leisure time activity associated with the difference in aerobic fitness level?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Exercise is good for your blood pressure: effects of endurance training and resistance training

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of aspirin to prevent colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse cardiovascular effects of rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy and safety of celecoxib in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective cyclooxygenase 2 inhibitors and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Coxibs and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of prostacyclin in the cardiovascular response to thromboxane A2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Balancing prostanoid activity in the human vascular system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Parecoxib, valdecoxib, and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of ibuprofen on cardioprotective effect of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonsteroidal anti-inflammatory drugs and the risk of intracerebral hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between naproxen use and protection against acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

NSAIDs and increased blood pressure. What is the clinical significance?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenases, the kidney, and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective COX-2 inhibition improves endothelial function in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Facile air oxidation of the conjugate base of rofecoxib (Vioxx™), a possible contributor to chronic human toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Parsing an enigma: the pharmacodynamics of aspirin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic aspirin and risk of peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961909-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(07)61909-6

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37044230&oldid=2175053002"